Add to ORKGAt present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresse
Splenic marginal zone lymphoma (SMZL) is an indolent lymphoma in which watch and wait (W&W) appr...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...
At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Background: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, ...
Splenic marginal zone lymphoma (SMZL) is a rare lymphoma belonging to the marginal zone lymphoprolif...
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and variou...
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and variou...
none13noFirst line therapy of patients with marginal zone lymphomas (MZL) is not well established an...
Splenic marginal zone lymphoma (SMZL) is an indolent disease that typically affects elderly patients...
Splenic marginal zone lymphoma (SMZL) is an indolent disease that typically affects elderly patients...
Optimal treatment for splenic marginal zone lymphoma (MZL) is not clearly established. Splenectomy h...
Splenic marginal zone lymphoma (SMZL) is an indolent lymphoma in which watch and wait (W&W) appr...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...
At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable dise...
Background: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, ...
Splenic marginal zone lymphoma (SMZL) is a rare lymphoma belonging to the marginal zone lymphoprolif...
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and variou...
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and variou...
none13noFirst line therapy of patients with marginal zone lymphomas (MZL) is not well established an...
Splenic marginal zone lymphoma (SMZL) is an indolent disease that typically affects elderly patients...
Splenic marginal zone lymphoma (SMZL) is an indolent disease that typically affects elderly patients...
Optimal treatment for splenic marginal zone lymphoma (MZL) is not clearly established. Splenectomy h...
Splenic marginal zone lymphoma (SMZL) is an indolent lymphoma in which watch and wait (W&W) appr...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...
Rituximab (®) provides high response rates and effective disease palliation in patients with splenic...